Literature DB >> 17898866

Functional analysis of the Aurora Kinase A Ile31 allelic variant in human prostate.

Noa Matarasso1, Anat Bar-Shira, Uri Rozovski, Serena Rosner, Avi Orr-Urtreger.   

Abstract

Overexpression of the centrosome-associated serine/threonine kinase Aurora Kinase A (AURKA) has been demonstrated in both advanced prostate cancer and high-grade prostatic intraepithelial neoplasia lesions. The single-nucleotide polymorphism T91A (Phe31Ile) has been implicated in AURKA overexpression and has been suggested as a low-penetrance susceptibility allele in multiple human cancers, including prostate cancer. We studied the transcriptional consequences of the AURKA Ile31 allele in 28 commercial normal prostate tissue RNA samples (median age, 27 years). Significant overexpression of AURKA was demonstrated in homozygous and heterozygous AURKA Ile31 prostate RNA (2.07-fold and 1.93-fold, respectively; P < .05). Expression levels of 1509 genes differentiated between samples homozygous for Phe31 alleles and samples homozygous for Ile31 alleles (P = .05). Gene Ontology classification revealed overrepresentation of cell cycle arrest, ubiquitin cycle, antiapoptosis, and angiogenesis-related genes. When these hypothesis-generating results were subjected to more stringent statistical criteria, overexpression of a novel transcript of the natural killer tumor recognition sequence (NKTR) gene was revealed and validated in homozygous Ile31 samples (2.6-fold; P < .05). In summary, our data suggest an association between the AURKA Ile31 allele and an altered transcriptome in normal non-neoplastic prostates.

Entities:  

Keywords:  Aurora Kinase A; NKTR; cancer; overexpression; prostate

Mesh:

Substances:

Year:  2007        PMID: 17898866      PMCID: PMC1993855          DOI: 10.1593/neo.07322

Source DB:  PubMed          Journal:  Neoplasia        ISSN: 1476-5586            Impact factor:   5.715


  47 in total

1.  LuCaP 35: a new model of prostate cancer progression to androgen independence.

Authors:  Eva Corey; Janna E Quinn; Kent R Buhler; Peter S Nelson; Jill A Macoska; Lawrence D True; Robert L Vessella
Journal:  Prostate       Date:  2003-06-01       Impact factor: 4.104

2.  Suppression of cell transformation by the cyclin-dependent kinase inhibitor p57KIP2 requires binding to proliferating cell nuclear antigen.

Authors:  H Watanabe; Z Q Pan; N Schreiber-Agus; R A DePinho; J Hurwitz; Y Xiong
Journal:  Proc Natl Acad Sci U S A       Date:  1998-02-17       Impact factor: 11.205

3.  A putative serine/threonine kinase encoding gene BTAK on chromosome 20q13 is amplified and overexpressed in human breast cancer cell lines.

Authors:  S Sen; H Zhou; R A White
Journal:  Oncogene       Date:  1997-05-08       Impact factor: 9.867

4.  A cyclophilin-related protein involved in the function of natural killer cells.

Authors:  S K Anderson; S Gallinger; J Roder; J Frey; H A Young; J R Ortaldo
Journal:  Proc Natl Acad Sci U S A       Date:  1993-01-15       Impact factor: 11.205

5.  Polymorphisms of STK15 (Aurora-A) gene and lung cancer risk in Caucasians.

Authors:  Jian Gu; Yubo Gong; Maosheng Huang; Charles Lu; Margaret R Spitz; Xifeng Wu
Journal:  Carcinogenesis       Date:  2006-08-21       Impact factor: 4.944

6.  Centrosome defects can account for cellular and genetic changes that characterize prostate cancer progression.

Authors:  G A Pihan; A Purohit; J Wallace; R Malhotra; L Liotta; S J Doxsey
Journal:  Cancer Res       Date:  2001-03-01       Impact factor: 12.701

7.  Array-based comparative genomic hybridization identifies localized DNA amplifications and homozygous deletions in pancreatic cancer.

Authors:  Murali D Bashyam; Ryan Bair; Young H Kim; Pei Wang; Tina Hernandez-Boussard; Collins A Karikari; Robert Tibshirani; Anirban Maitra; Jonathan R Pollack
Journal:  Neoplasia       Date:  2005-06       Impact factor: 5.715

8.  Identifying biological themes within lists of genes with EASE.

Authors:  Douglas A Hosack; Glynn Dennis; Brad T Sherman; H Clifford Lane; Richard A Lempicki
Journal:  Genome Biol       Date:  2003-09-11       Impact factor: 13.583

9.  RNASEL mutation screening and association study in Ashkenazi and non-Ashkenazi prostate cancer patients.

Authors:  Avi Orr-Urtreger; Anat Bar-Shira; Dani Bercovich; Noa Matarasso; Uri Rozovsky; Serena Rosner; Sonya Soloviov; Gad Rennert; Luna Kadouri; Ayala Hubert; Hanna Rennert; Haim Matzkin
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2006-03       Impact factor: 4.254

10.  Cloning of p57KIP2, a cyclin-dependent kinase inhibitor with unique domain structure and tissue distribution.

Authors:  M H Lee; I Reynisdóttir; J Massagué
Journal:  Genes Dev       Date:  1995-03-15       Impact factor: 11.361

View more
  18 in total

1.  Bioactive tanshinone I inhibits the growth of lung cancer in part via downregulation of Aurora A function.

Authors:  Yanli Li; Yi Gong; Linglin Li; Hamid M Abdolmaleky; Jin-Rong Zhou
Journal:  Mol Carcinog       Date:  2012-03-02       Impact factor: 4.784

2.  Association of genetic and non-genetic risk factors with the development of prostate cancer in Malaysian men.

Authors:  Khamsigan Munretnam; Livy Alex; Nurul Hanis Ramzi; Jagdish Kaur Chahil; I S Kavitha; Nikman Adli Nor Hashim; Say Hean Lye; Sharmila Velapasamy; Lian Wee Ler
Journal:  Mol Biol Rep       Date:  2014-01-18       Impact factor: 2.316

3.  Bioactive tanshinones in Salvia miltiorrhiza inhibit the growth of prostate cancer cells in vitro and in mice.

Authors:  Yi Gong; Yanli Li; Yin Lu; Linglin Li; Hamid Abdolmaleky; George L Blackburn; Jin-Rong Zhou
Journal:  Int J Cancer       Date:  2010-11-03       Impact factor: 7.396

4.  The War on Cancer rages on.

Authors:  Alnawaz Rehemtulla
Journal:  Neoplasia       Date:  2009-12       Impact factor: 5.715

5.  Neoplasia: the second decade.

Authors:  Alnawaz Rehemtulla
Journal:  Neoplasia       Date:  2008-12       Impact factor: 5.715

6.  SEPT14 Is Associated with a Reduced Risk for Parkinson's Disease and Expressed in Human Brain.

Authors:  Liron Rozenkrantz; Ziv Gan-Or; Mali Gana-Weisz; Anat Mirelman; Nir Giladi; Anat Bar-Shira; Avi Orr-Urtreger
Journal:  J Mol Neurosci       Date:  2016-04-26       Impact factor: 3.444

7.  Bladder cancer SNP panel predicts susceptibility and survival.

Authors:  Angeline S Andrew; Jiang Gui; Arthur C Sanderson; Rebecca A Mason; Elaine V Morlock; Alan R Schned; Karl T Kelsey; Carmen J Marsit; Jason H Moore; Margaret R Karagas
Journal:  Hum Genet       Date:  2009-03-01       Impact factor: 4.132

8.  Tanshinones inhibit the growth of breast cancer cells through epigenetic modification of Aurora A expression and function.

Authors:  Yi Gong; Yanli Li; Hamid M Abdolmaleky; Linglin Li; Jin-Rong Zhou
Journal:  PLoS One       Date:  2012-04-02       Impact factor: 3.240

9.  KUD773, a phenylthiazole derivative, displays anticancer activity in human hormone-refractory prostate cancers through inhibition of tubulin polymerization and anti-Aurora A activity.

Authors:  Chia-Chun Yu; Shih-Ping Liu; Jui-Ling Hsu; John Ta Hsu; Konstantin V Kudryavtsev; Jih-Hwa Guh
Journal:  J Biomed Sci       Date:  2015-01-07       Impact factor: 8.410

10.  DNA repair gene variants are associated with an increased risk of myelodysplastic syndromes in a Czech population.

Authors:  Monika Belickova; Michaela Dostalova Merkerova; Eliska Stara; Jitka Vesela; Dana Sponerova; Dana Mikulenkova; Radim Brdicka; Radana Neuwirtova; Anna Jonasova; Jaroslav Cermak
Journal:  J Hematol Oncol       Date:  2013-01-22       Impact factor: 17.388

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.